1. Home
  2. News
  3. Bio-key International, Inc.
  4. BIO-key Trims 2024 Net Loss 49% to $4.3M, Reflecting Higher Gross Margin and Lower Operating Costs, Offsetting 11% Re...
Bio-key International, Inc. news

Investor announcements, newest first.

Close
Company news
Bio-key International, Inc.
Mar 27, 2025 at 11:58 AM UTC
Original
ELI5

BIO-key Trims 2024 Net Loss 49% to $4.3M, Reflecting Higher Gross Margin and Lower Operating Costs, Offsetting 11% Revenue Decrease Due to Business Transition; Hosts Investor Call Today at 10am ET

HOLMDEL, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, announced results for its fourth quarter (Q4’24) and year ended December 31, 2024 (2024). BIO-key’s 2023 results, which were restated and filed with the Company’s 2023 Form 10-K, are reflected in this release for comparison purposes. BIO-key will host an investor call today, Thursday, March 27th at 10:00am ET (details below).

BIO-key CEO, Mike DePasquale commented, “From a strategic standpoint, we substantially strengthened our business in 2024, growing our high-margin software license fee revenue by 20% while exiting our low margin services relationship with Swivel Secure to focus on BIO-key solutions such as PortalGuard IAM and our Identity-Bound Biometrics. This transition away from Swivel Secure licensed solutions resulted in an 11% decline in 2024 revenue, but enabled us to substantially improve overall profitability despite lower revenue.

“We also reduced operating expenses by 6% in 2024 and reduced cash used in operations by 23% to $2.91M in 2024 from $3.79M in 2023. With this transition behind us, we are in a much stronger position to grow and convert top-line revenue into bottom-line contribution.”

Recent Highlights

  • Partnered with California Ed Tech JPA to make BIO-key solutions available to 195 member institutions serving over 2.6M students.

  • Higher Education customers with 30,000+ users migrated to BIO-key’s PortalGuard IDaaS platform from its on-premises solution and Wyoming Department of Education deployed PortalGuard IDaaS.

  • National Bank of Egypt deployed BIO-key Multi-Factor Authentication and Single Sign-On solutions.

  • Initiated collaboration with engineering solutions provider Guinn Partners to transform access control and cybersecurity for IoT and autonomous systems.

  • Partnered with Fiber Food Systems to enhance security and efficiency in the Food Tech sector.

  • Secured $910K order to upgrade Financial Services firm to “fingerprint only,” one-to-many biometric ID technology for its customers.

  • Secured $500K in biometric user authentication orders from leading international defense ministry; with follow- on orders expected in 2025 under new purchase agreement.

  • Launched Amazon Web Services (AWS) Marketplace availability for PortalGuard and Identity-Bound Biometrics.

Mr. DePasquale, continued, “Moving forward, we are seeing very encouraging order demand for our solutions in national defense, financial services and education applications and particular strength in EMEA countries. We are seeing growing interest in our unique capabilities in passwordless, phoneless and tokenless authentication solutions which are best positioned to meet the most pressing security and usability challenges. Our biometric solutions are gaining solid traction in international markets across government, financial services and civil defense applications.

“For example, in Q4’24 we secured a $910K contract with a long-time financial services client to implement our biometric identification technology across its branches. The customer has already enrolled fingerprint biometrics for over 25M end-users and is now upgrading to BIO-key’s “fingerprint-only,” one-to-many identification system. Our solution is expected to trim approximately 30 seconds from each customer interaction, resulting in both an improved customer experience and substantial long-term savings.

“Our longstanding relationship with one of the world’s most esteemed defense ministries saw expanded deployment of our biometric solutions in 2024, a trend we expect to continue in 2025 and beyond. We currently provide authentication and digital security services for over 80,000 ministry personnel and believe that deployment could double or triple in coming years. To date, the ministry has generated $3.3M in total hardware and license revenue, and we are now working under a new long term procurement agreement initiated in Q3 2024.

“This past January, we forged a partnership with the National Bank of Egypt, which is integrating BIO-key’s PortalGuard IAM platform and an industry-leading Identity Governance solution. This project, led by our partner, Raya Information Technology, leverages PortalGuard’s advanced IAM, MFA, and SSO capabilities to secure the digital identities of the bank’s 30,000 employees, and we believe there is potential down the road for this solution to be utilized with its customers.

“BIO-key has also built an established and growing presence in education across over 100 institutions serving over 4M end users. In January, three additional colleges and universities migrated to PortalGuard IDaaS and the Wyoming Department of Education deployed PortalGuard IDaaS, adding a total of over 50,000 IDaaS end users. Building on this momentum, after an extensive RFP and review process, we executed a strategic partnership and Joint Purchase Agreement (JPA) with California’s Education Technology Joint Powers Authority (Ed Tech JPA). The agreement makes PortalGuard an approved IAM solution for the alliance’s 195 K-12 schools and districts, collectively serving over 2.6M students, uniquely positioning our offerings to comply solve Ed Tech JPA member IAM requirements, including compliance with emerging restrictions on the use of personal mobile devices in schools.

“In an effort to seed future market opportunities, in December we announced a strategic collaboration with Fiber Food Systems to explore IAM use cases across the food industry. As part of this agreement, we also acquired shares of Boumarang, Inc. from Fiber in exchange for BIO-key stock. Boumarang is a pioneering force in sustainable, AI-driven, hydrogen-powered, long-range drone technology, a developing market with a clear need for a state-of-the-art IAM solutions. The equity exchange strengthened our balance sheet and paved the way to a strategic collaboration with Guinn Partners to integrate our biometric technology with Guinn’s expertise in IoT and autonomous systems, targeting applications across aerospace, defense, healthcare, logistics and smart cities. These initiatives will take time to develop, but we believe that each of them has the potential to create attractive new commercial opportunities for BIO-key.

“We are off to a strong start in 2025 and believe we are well positioned to deliver improved top- and bottom-line performance. However, given the timing of large customer orders, our financial performance has the potential to fluctuate significantly on a quarter-to-quarter basis. Given increasing interest in our biometric solutions, growing adoption of passwordless, phoneless and tokenless IAM solutions, and the transition we executed in 2024 to a focus on higher-margin BIO-key solutions, we are very optimistic regarding our prospects this year. We remain focused on reducing costs to lower our breakeven level as we continue to explore new markets and strategic partnerships that could advance our path to sustained profitability and positive operating cash flow.”

Financial Results
Please note that the audit our FY2024 financial statements has not been completed by our independent registered public accounting firm as of the date of this press release and are therefore subject to change.

2024 revenues decreased approximately 11% to $6.9M from $7.8M in 2023, largely due to BIO-key’s exit from a Swivel Secure Limited (SSL) distribution agreement and transition to selling BIO-key branded solutions in the EMEA region. The impact of this strategic decision contributed to more high-margin software license fee revenue and a reduction in services revenue from third-party products which carry a much lower gross margin. As a result, 2024 license fee revenue increased 20% to $5.2M in 2024 vs. $4.3M in 2023; service fees declined 50% to $1.1M in 2024 from $2.2 million in 2023; and hardware revenue declined 47% to $0.6M in 2024 from $1.2M in 2023.

In Q4’24 license fee revenue increased 77% to $1.0M; services revenue decreased 28% to $0.3M and hardware revenue declined 88% to $0.1M, also reflecting the impacts of the strategic transition from SSL products and services toward BIO-key solutions.

Gross profit grew to $5.6M in 2024 from $1.4M in 2023, due to a $3.6M hardware reserve taken in 2023 and the impact of growth in higher-margin license sales and a reduction in lower-margin services and hardware revenue. Exiting the SSL agreement contributed to lower costs to support deployments, including software license fees included in sales of Swivel Secure offerings vs. BIO-key’s internally developed software solutions. This resulted in gross profit increasing to $1.2M in Q4’24 vs. negative $95,496 in Q4’23, which included a $1.1M hardware reserve. Both Q4’24 and 2024 gross profit benefited from the sale of $213,005 of fully reserved hardware inventory.

BIO-key reduced its operating expenses by $606,409 to $9.7M in 2024 from $10.3M in 2023, due to a reduction of SG&A costs by $722,563, partially offset by a $116,154 increase in research, development and engineering expense to support new product development. Proactive cost reductions included lower headquarters expenses, sales personnel costs, and marketing show expenses, partially offset by an increase in professional services, principally related to financing activities. BIO-key’s Q4’24 operating expenses were flat year-over-year at $2.6M.

Reflecting greater gross profit and lower operating expenses, BIO-key’s 2024 net loss improved to $4.3M, or ($2.10) per share, from a net loss of $8.7M, or ($15.21) per share, in 2023. Similarly, BIO-key’s Q4’24 net loss improved to $1.6M, or ($0.53) per share, vs. $2.4M, or ($3.99) per share, in Q4’23. 2023 Results included hardware reserves of $3.6M and $1.086M in 2023 and Q4’23, respectively. 2024 results included a positive hardware reserve adjustment of $213,005 in Q4 for the sale of hardware that was previously reserved.

Balance Sheet
As of December 31, 2024, BIO-key had $1.9M of current assets, including $438,000 of cash and cash equivalents, $0.8M of net accounts receivable and due from factor, and $378,000 of inventory. This compares to current assets of $2.6M at December 31, 2023, including approximately $511,000 of cash and cash equivalents, $1.3M of net accounts receivable and due from factor, and $446,000 of inventory.

Conference Call Details

Date / Time:

Thursday, March 27th at 10 a.m. ET

Call Dial In #:

1-877-418-5460 U.S. or 1-412-717-9594 Int’l

Live Webcast / Replay:

Webcast & Replay Link – Available for 3 months.

Audio Replay:

1-877-344-7529 U.S. or 1-412-317-0088 Int’l; code 6114035

 

 

About BIO-key International, Inc. (www.BIO-key.com)

BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.

BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia and other foreign markets; our ability to migrate Swivel Secure customers to BIO-key and Portal Guard offerings; fluctuations in foreign currency exchange rates; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence of the restatement of our financial statements, including any consequences of non-compliance with Securities and Exchange Commission and Nasdaq periodic reporting requirements; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future;, any disruption to our business that may occur on a longer-term basis should we be unable to continue to maintain effective internal controls over financial reporting, and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.

Engage with BIO-key

Facebook – Corporate:

https://www.facebook.com/BIOkeyInternational/

LinkedIn – Corporate:

https://www.linkedin.com/company/bio-key-international

X – Corporate:

@BIOkeyIntl 

X – Investors:

@BIO_keyIR

StockTwits:

BIO_keyIR

 

 

Investor Contacts

William Jones, David Collins
Catalyst IR
[email protected] or 212-924-9800

 

BIO-key International, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)

 

 

Three Months Ended

 

 

Twelve Months Ended

 

 

December 31,

 

 

December 31,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Services

$

344,444

 

 

$

478,005

 

 

$

1,108,506

 

 

$

2,218,885

 

License fees

 

1,023,701

 

 

 

577,669

 

 

 

5,189,370

 

 

 

4,342,010

 

Hardware

 

94,133

 

 

 

769,427

 

 

 

631,695

 

 

 

1,194,010

 

Total revenues

 

1,462,278

 

 

 

1,825,101

 

 

 

6,929,571

 

 

 

7,754,905

 

Costs and other expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of services

 

73,317

 

 

 

221,940

 

 

 

396,274

 

 

 

861,936

 

Cost of license fees

 

146,122

 

 

 

152,000

 

 

 

589,505

 

 

 

1,174,919

 

Cost of hardware

 

255,927

 

 

 

460,157

 

 

 

516,611

 

 

 

700,231

 

Cost of hardware - reserve

 

(213,005

)

 

 

1,086,500

 

 

 

(213,005

)

 

 

3,586,500

 

Total costs and other expenses

 

262,361

 

 

 

1,920,597

 

 

 

1,289,385

 

 

 

6,323,586

 

Gross profit

 

1,199,917

 

 

 

(95,496

)

 

 

5,640,186

 

 

 

1,431,319

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

1,815,155

 

 

 

2,040,438

 

 

 

7,140,147

 

 

 

7,862,710

 

Research, development and engineering

 

812,072

 

 

 

587,900

 

 

 

2,511,080

 

 

 

2,394,926

 

Total Operating Expenses

 

2,627,227

 

 

 

2,628,338

 

 

 

9,651,227

 

 

 

10,257,636

 

Operating loss

 

(1,427,310

)

 

 

(2,723,834

)

 

 

(4,011,041

)

 

 

(8,826,317

)

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

57

 

 

 

5,589

 

 

 

110

 

 

 

11,533

 

Gain from sale of asset

 

 

 

 

 

20,000

 

 

 

 

 

 

 

20,000

 

Loss on foreign currency transactions

 

(13,004

)

 

 

(24,000

)

 

 

(13,004

)

 

 

(39,000

)

Loan fee amortization

 

(60,000

)

 

 

-

 

 

 

(124,000

)

 

 

-

 

Change in fair value of convertible note

 

-

 

 

 

131,497

 

 

 

-

 

 

 

396,203

 

Interest expense

 

(66,932

)

 

 

(58,890

)

 

 

(175,755

)

 

 

(218,270

)

Total other income (expense), net

 

(139,879

)

 

 

74,196

 

 

 

(312,649

)

 

 

170,466

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before provision for income tax

 

(1,567,189

)

 

 

(2,649,638

)

 

 

(4,323,690

)

 

 

(8,655,851

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Provision for (income tax) tax benefit

 

-

 

 

 

276,825

 

 

 

-

 

 

 

134,014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

$

(1,567,189

)

 

$

(2,372,813

)

 

$

(4,323,690

)

 

$

(8,521,837

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

$

(1,567,189

)

 

$

(2,372,813

)

 

$

(4,323,690

)

 

$

(8,521,837

)

Other comprehensive income (loss) – Foreign currency translation adjustment

 

(25,409

)

 

 

138,029

 

 

 

26,469

 

 

 

265,423

 

Comprehensive loss

$

(1,592,598

)

 

$

(2,234,784

)

 

$

(4,297,221

)

 

$

(8,256,414

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted Loss per Common Share*

$

(0.53

)

 

$

(3.99

)

 

$

(2.10

)

 

$

(15.21

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

3,032,240

 

 

 

560,278

 

 

 

2,059,884

 

 

 

560,278

 

 

*Periods reflect impact of BIO-key’s 1-for-18 reverse stock split effective December 21, 2023.

 

Please note that the audit our FY2024 financial statements has not been completed by our independent registered public accounting firm as of the date of this press release and are therefore subject to change. 


 

BIO-key International, Inc. and Subsidiaries
CONSOLIDATED BALANCE SHEETS

 

 

 

December 31,

 

 

 

2024

 

 

2023

 

ASSETS

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

437,604

 

 

$

511,400

 

Accounts receivable, net

 

 

718,229

 

 

 

1,201,526

 

Due from factor

 

 

74,170

 

 

 

99,320

 

Inventory, net of reserve

 

 

378,307

 

 

 

445,740

 

Prepaid expenses and other

 

 

278,648

 

 

 

364,171

 

Total current assets

 

 

1,886,958

 

 

 

2,622,157

 

Equipment and leasehold improvements, net

 

 

140,198

 

 

 

220,177

 

Capitalized contract costs, net

 

 

409,426

 

 

 

229,806

 

Deposits and other assets

 

 

7,976

 

 

 

-

 

Operating lease right-of-use assets

 

 

73,372

 

 

 

36,905

 

Other assets

 

 

5,000,000

 

 

 

-

 

Intangible assets, net

 

 

1,097,630

 

 

 

1,407,990

 

Total non-current assets

 

 

6,728,602

 

 

 

1,894,878

 

TOTAL ASSETS

 

$

8,615,560

 

 

$

4,517,035

 

 

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

 

 

 

Accounts payable

 

$

818,187

 

 

$

1,316,014

 

Accrued liabilities

 

 

1,278,732

 

 

 

1,305,848

 

Note payable

 

 

1,525,977

 

 

 

-

 

Government loan – BBVA Bank, current portion

 

 

132,731

 

 

 

138,730

 

Deferred revenue - current

 

 

773,267

 

 

 

414,968

 

Operating lease liabilities, current portion

 

 

24,642

 

 

 

37,829

 

Total current liabilities

 

 

4,553,536

 

 

 

3,213,389

 

Deferred revenue, net of current portion

 

 

196,237

 

 

 

28,296

 

Deferred tax liability

 

 

22,998

 

 

 

22,998

 

Government loan – BBVA Bank, net of current portion

 

 

44,762

 

 

 

188,787

 

Operating lease liabilities, net of current portion

 

 

48,994

 

 

 

-

 

Total non-current liabilities

 

 

312,991

 

 

 

240,081

 

TOTAL LIABILITIES

 

 

4,866,527

 

 

 

3,453,470

 

 

 

 

 

 

 

 

 

 

Commitments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Common stock — authorized, 170,000,000 shares; issued and outstanding; 3,715,483 and 1,032,777 of $.0001 par value at December 31, 2024 and December 31, 2023, respectively

 

 

372

 

 

 

103

 

Additional paid-in capital

 

 

133,030,271

 

 

 

126,047,851

 

Accumulated other comprehensive loss

 

 

49,290

 

 

 

22,821

 

Accumulated deficit

 

 

(129,330,900

)

 

 

(125,007,210

)

TOTAL STOCKHOLDERS’ EQUITY

 

 

3,749,033

 

 

 

1,063,565

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 

$

8,615,560

 

 

$

4,517,035

 

 

All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.

 

Please note that the audit our FY2024 financial statements has not been completed by our independent registered public accounting firm as of the date of this press release and are therefore subject to change. 


 

BIO-key International, Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

 

Years ended December 31,

 

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

 

 

CASH FLOW FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net loss

 

$

(4,323,690

)

 

$

(8,521,837

)

Adjustments to reconcile net loss to cash used for operating activities:

 

 

 

 

 

 

 

 

Depreciation

 

 

93,026

 

 

 

75,136

 

Amortization of intangible assets and write-off

 

 

304,983

 

 

 

354,558

 

Interest payable on Note

 

 

164,589

 

 

 

-

 

Loss on foreign currency

 

 

13,004

 

 

 

39,000

 

Reserve for inventory

 

 

(213,005

)

 

 

3,586,500

 

Allowance for doubtful account

 

 

(372,532

)

 

 

750,000

 

Amortization of debt discount

 

 

124,000

 

 

 

-

 

Amortization of capitalized contract costs

 

 

175,900

 

 

 

171,291

 

Share based and warrant compensation for employees and consultants

 

 

225,245

 

 

 

226,725

 

Stock based fees to directors

 

 

18,006

 

 

 

39,007

 

Bad debt expense

 

 

100,000

 

 

 

100,000

 

Change in fair value of convertible note

 

 

-

 

 

 

(396,203

)

Deferred income tax benefit

 

 

-

 

 

 

(134,014

)

Amortization of operating lease right-of-use assets

 

 

79,521

 

 

 

-

 

Change in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

855,829

 

 

 

(428,742

)

Due from factor

 

 

25,150

 

 

 

(49,820

)

Capitalized contract costs

 

 

(355,520

)

 

 

(118,028

)

Deposits

 

 

(7,976

)

 

 

-

 

Right of use asset

 

 

(115,988

)

 

 

160,449

 

Inventory

 

 

280,438

 

 

 

402,129

 

Prepaid expenses and other

 

 

85,523

 

 

 

(21,465

)

Accounts payable

 

 

(502,987

)

 

 

57,725

 

Income tax payable

 

 

-

 

 

 

(121,764

)

Accrued liabilities

 

 

(27,116

)

 

 

275,561

 

Deferred revenue

 

 

526,240

 

 

 

(71,288

)

Operating lease liabilities

 

 

(66,712

)

 

 

(168,376

)

Net cash used for operating activities

 

 

(2,914,072

)

 

 

(3,793,456

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Capital expenditures

 

 

(13,047

)

 

 

(1,000

)

Net cash used for investing activities

 

 

(13,047

)

 

 

(1,000

)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Proceeds from public offerings

 

 

 

 

 

 

4,296,260

 

Repayment of convertible notes

 

 

 

 

 

 

(2,200,000

)

Proceeds from the exercise of warrants

 

 

1,908,099

 

 

 

320

 

Costs incurred for issuance of common stock

 

 

(172,350

)

 

 

(561,367

)

Proceeds from issuance of note payable

 

 

2,000,000

 

 

 

-

 

Repayment of note payable

 

 

(762,611

)

 

 

-

 

Repayment of government loan

 

 

(150,024

)

 

 

(119,251

)

Proceeds from Employee Stock Purchase Plan

 

 

3,740

 

 

 

17,478

 

Net cash (used in) provided by financing activities

 

 

2,826,854

 

 

 

1,433,440

 

Effect of exchange rate changes

 

 

26,469

 

 

 

236,894

 

NET DECREASE IN CASH AND CASH EQUIVALENTS

 

 

(73,796

)

 

 

(2,124,122

)

CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR

 

 

511,400

 

 

 

2,635,522

 

CASH AND CASH EQUIVALENTS, END OF YEAR

 

$

437,604

 

 

$

511,400

 

 

All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.

 

Please note that the audit our FY2024 financial statements has not been completed by our independent registered public accounting firm as of the date of this press release and are therefore subject to change.